Funding Based Primarily on Operating Cash Flow and Borrowings from Financial Institutions
First written in FY2017. 7 of 17 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2026.
13 other companies' latest entry also says "Other".
- FY2026Increase in drawn commitment-line balanceAnnual report
「Commitment line total ¥49,500 million; drawn balance 30,032; undrawn amount 19,468」
The total commitment line remained at ¥49.5 billion, but the drawn balance increased from ¥16.325 billion in the previous period to ¥30.032 billion. Of this, ¥26.5 billion is for construction of the new pharmaceutical manufacturing plant. - FY2025Increase in drawn commitment-line balanceAnnual report
「Commitment line total ¥40,000 million ¥49,500 million; drawn balance 6,500 16,325; undrawn amount 33,500 33,175」
The ¥49.5 billion total commitment line was maintained, including ¥26.5 billion for the new pharmaceutical manufacturing plant. The drawn balance increased from ¥6.5 billion at the end of the previous period to ¥16.325 billion. - FY2025-H1AdvancedAnnual report
「To secure flexible and stable funding sources for our group’s sustainable global growth, we have entered into commitment line agreements totaling ¥49.5 billion with financial institutions to secure working capital as a backup line. Of this amount, ¥26.5 billion relates to financing for construction of the new pharmaceutical manufacturing plant.」
The total commitment line was increased from ¥40.0 billion at the end of the previous fiscal year to ¥49.5 billion, with ¥26.5 billion of the amount allocated to construction of the new pharmaceutical manufacturing plant. The drawn balance at the end of September was ¥8.612 billion. - FY2024AdvancedAnnual report
「We have entered into commitment line agreements totaling ¥40.0 billion with financial institutions to secure working capital as a backup line. Of this amount, ¥17.0 billion relates to agreements newly entered into to finance construction of the new pharmaceutical manufacturing plant.」
The total commitment line was increased from ¥15.5 billion to ¥40.0 billion, and a new agreement was entered into to use ¥17.0 billion of this amount as bridge financing until subsidies for construction of the new pharmaceutical manufacturing plant are received. - FY2024-Q2RestatedAnnual report
「Although our group has not currently been affected by COVID-19, the outlook for global conditions remains uncertain. To secure flexible and stable funding sources for sustainable global growth, our group has entered into commitment line agreements totaling ¥23.0 billion with financial institutions to secure working capital as a backup line.」
The company maintains a ¥23.0 billion commitment line as a working-capital backup line. The drawn balance at the end of September was ¥6.5 billion, leaving an undrawn amount of ¥16.5 billion. - FY2024-Q1Increase in commitment line and drawn balanceAnnual report
「Commitment line total ¥15,500 million ¥23,000 million; drawn balance 6,000 6,500; undrawn amount 9,500 16,500」
The total working-capital backup line was increased from ¥15.5 billion to ¥23.0 billion, and the drawn balance also increased from ¥6.0 billion to ¥6.5 billion. - FY2023Increase in drawn commitment line balanceAnnual report
「Commitment line total ¥15,500 million; drawn balance 6,000; undrawn amount 9,500」
The total commitment line remained at ¥15.5 billion, but the drawn balance increased from ¥3.0 billion in the previous period to ¥6.0 billion, leaving an undrawn amount of ¥9.5 billion. - FY2023-Q2RestatedAnnual report
「Commitment line total ¥15,500 million; drawn balance 3,000; undrawn amount 12,500」
The company maintains a ¥15.5 billion commitment line as a working-capital backup line, with a drawn balance of ¥3.0 billion and an undrawn amount of ¥12.5 billion. - FY2022-Q2Update to commitment line balancesAnnual report
「Commitment line total ¥15,500 million; drawn balance 3,000; undrawn amount 12,500」
The company maintained a ¥15.5 billion working-capital backup line. At the end of the second quarter, the drawn balance was ¥3.0 billion and the undrawn amount was ¥12.5 billion, as disclosed. - FY2021-Q2AdvancedAnnual report
「During the first six months of the current consolidated fiscal year, we entered into commitment line agreements totaling ¥15.5 billion with financial institutions to secure working capital as a backup line.」
The total commitment lines for working capital backup were increased to ¥15.5 billion. Borrowings drawn as of the end of the second quarter were ¥3.450 billion. - FY2021-Q1AdvancedAnnual report
「Previous consolidated fiscal year (31 March 2020) Total commitment lines－million yen Borrowings drawn－ Available amount－ First quarter of the current consolidated fiscal year (30 June 2020) Total commitment lines ¥15,000 million Borrowings drawn 3,450 Available amount 11,550」
Commitment lines totaling ¥15.0 billion were established as backup lines for working capital, and ¥3.450 billion had been drawn as of the end of the first quarter. The funding policy progressed from entering into the agreements to actually drawing on the facilities. - FY2020AdvancedAnnual report
「We entered into commitment line agreements totaling ¥15.0 billion with financial institutions in April and May 2020 to secure working capital as a backup line.」
As a liquidity measure during the COVID-19 pandemic under the policy of using operating cash flow as the primary funding source and borrowings to cover shortfalls, the company entered into commitment lines totaling ¥15.0 billion in April and May 2020. - FY2020-Q3AdvancedAnnual report
「Current liabilities increased by ¥554 million from the end of the previous consolidated fiscal year to ¥9.239 billion, mainly due to an increase in short-term borrowings. Non-current liabilities increased by ¥1.716 billion to ¥4.674 billion, mainly due to an increase in long-term borrowings. The increase in these borrowings was associated with the expansion of research-related facilities.」
Short- and long-term borrowings increased in connection with the expansion of research-related facilities. The policy of using operating cash flow as the primary funding source and borrowings to cover shortfalls was implemented through borrowings specifically associated with the facility expansion. - FY2020-Q2AdvancedAnnual report
「The increase in these borrowings was associated with the expansion of research-related facilities. Cash provided by financing activities was ¥2.595 billion, mainly comprising a net increase of ¥1.0 billion in short-term borrowings and ¥2.2 billion in proceeds from long-term borrowings.」
Short- and long-term borrowings increased in connection with the expansion of research-related facilities, putting into practice the policy of using borrowings to fund shortfalls where operating cash flow is insufficient. - FY2019RestatedAnnual report
「These funding needs are met primarily from cash flow from operating activities, with borrowings from financial institutions used when cash flow is insufficient.」
Reconfirmed the policy of funding working capital, research and development expenses and capital investment primarily from operating cash flow, with borrowings from financial institutions used when necessary. - FY2018RestatedAnnual report
「These funding needs are met primarily from cash flow from operating activities, with borrowings from financial institutions used when cash flow is insufficient.」
Reconfirmed the policy of funding working capital, research and development expenses and capital investment primarily from operating cash flow, with borrowings from financial institutions used when necessary. - FY2017First statedAnnual report
「These funding needs are met primarily through cash flow from operating activities and borrowings from financial institutions.」
For funding needs including raw materials, research and development expenses, selling expenses and capital investment, the company for the first time explicitly stated a funding policy based primarily on operating cash flow and borrowings from financial institutions.